Can a virus injected into brain tumors fight recurrence?

NCT ID NCT06614855

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether an experimental virus called C134 is safe when injected directly into the brain tumor in people with recurrent malignant glioma, including glioblastoma. Participants receive two doses of the virus during surgery to remove the tumor. The study focuses on safety and tolerability, and will also track survival and tumor progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
C134, an experimental virus injected directly into the brain tumor
What this could lead to
If safe and effective, this approach could offer a new way to treat recurrent brain tumors that have not responded to standard therapy.
What could go wrong
This is an early, small trial focused on safety, not effectiveness. The virus may not shrink tumors, and there are risks from injecting into the brain, including swelling or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Alabama at Birmingham Hospital

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.